Associate Professor, Medicine, UCSF School of Medicine
Gastroenterology
Dr. Fernando Velayos, MD
|
|
Give Review
Doctor Fernando Velayos, MD practices Gastroenterology. He went to medical school at University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a top medical university. University of California San Francisco School of Medicine has a rank of 3 in research and a 3 in primary care He has 1 awards "CMS Meaningful Use Stage 1 Certification". Dr. Fernando Velayos is a published physician as well. He has 46 publications published. The latest was: Colorectal cancer screening and surveillance in the elderly: updates and controversies. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Colorectal cancer screening and surveillance in the elderly: updates and controversies.
- Colorectal Cancer of the Elderly.
- Colorectal cancer and the elderly.
- On the Question of Ethnicity and Its Impact on IBD-Related Outcomes.
- Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States.
- Racial and Ethnic Differences in Health Care Utilization and Outcomes Among Ulcerative Colitis Patients in an Integrated Health-Care Organization.
- Avoiding Rash Decision Making: Skin Cancer Screening Inflammatory Bowel Disease.
- Serologic Markers Associated with Development of Crohn's Disease After Ileal Pouch Anal Anastomosis for Ulcerative Colitis.
- Systematic Review: The Role of Race and Socioeconomic Factors on IBD Healthcare Delivery and Effectiveness.
- A Test-Based Strategy is More Cost Effective than Empiric Dose-Escalation for Patients with Crohn's Disease Who Lose Responsiveness to Infliximab.
- Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.
- Incidence and Mortality of Colorectal Adenocarcinoma in Persons with Inflammatory Bowel Disease from 1998 to 2010.
- Colonoscopy after CT Diagnosis of Diverticulitis to Exclude Colon Cancer: A Systematic Literature Review.
- Early predictors of severe lower gastroIntestinal bleeding and adverse outcomes: a prospective study.
- Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's Disease.
- The mechanism of microsatellite instability is different in synchronous and metachronous Colorectal cancer.
- Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines.
- Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a Systematic review and metaanalysis of observational studies.
- Risk of intestinal Cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota.
- Predictive and protective factors associated with Colorectal cancer in ulcerative colitis: A case-control study.
- Incidence and prognosis of Colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota.
- Risk factors for Colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota.
- Management of steroid-dependent Ulcerative colitis: immunomodulatory agents, biologics, or surgery?
- Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update.
- The fungus among us.
- Tumor histology helps to identify Lynch syndrome among Colorectal cancer patients.
- Gastroenterologists' attitudes and self-reported practices regarding inflammatory bowel Disease.
- Positioning biologic therapy for Crohn's Disease and ulcerative colitis.
- Patterns of infliximab use among Crohn's Disease patients in a community setting.
- Forecasting cyclosporine success or failure.
- Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active Ulcerative colitis.
- Colon Cancer surveillance in inflammatory bowel disease patients: current and emerging practices.
- Time trends in therapies and outcomes for adult inflammatory bowel Disease, Northern California, 1998-2005.
- Deciding to operate for low-grade Colorectal dysplasia in ulcerative colitis: how much does the colon cost, how much is it worth?
- Cost effectiveness of Ulcerative colitis surveillance in the setting of 5-aminosalicylates.
- Timing of myelosuppression during thiopurine therapy for inflammatory bowel Disease: implications for monitoring recommendations.
- Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride?
- The good, the bad, and the ugly: adverse events and Crohn's therapies.
- Surgery for low-grade Colorectal dysplasia in ulcerative colitis: decisions, decisions.
- Incidence, prevalence, and time trends of pediatric inflammatory bowel Disease in Northern California, 1996 to 2006.
- The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's Disease: one size does not fit all.
- Viral hepatitis and inflammatory bowel Disease.
- Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery System.
- Colorectal Cancer Screening and Surveillance in the Elderly Patient.
- Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe Group.
Schools
University Of California San Francisco School Of Medicine
University Ca Sf School Of Med
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Manometry
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
- Aetna HMO
- Basic HMO
- Choice Plus POS II
- Vitalidad Plus California Con Aetna
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Access Plus Savenet
- Enhanced Exclusive for Small Business HMO
- Local Access Plus HMO
- Brown & Toland Physicians
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Delta Health System
- First Health (Coventry Health Care) PPO
- Golden Rule
- Blue & Gold HMO
- Employer Group HMO
- Medicare Advantage PFFS
- WholeCare Network HMO
- Humana
- Medical Mutual of Ohio
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- PacificSource
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
UCSF -
University of California San Francisco School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1942318928 | |
| NPPES Provider LastName | VELAYOS | |
| NPPES Provider FirstName | FERNANDO | |
| NPPES Provider ZIPCode | 941153465 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 511.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1942318928 |
| Last Name Of The Provider | VELAYOS |
| First Name Of The Provider | FERNANDO |
| View All |
Similar Doctors
|
|
Dr. James W. Ostroff, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane S. Melnick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan D. Pritikin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tami Daugherty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aristotle E. Mendiola, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chuong T. Tran, MD |